SCA
SMMT icon

Snowden Capital Advisors’s Summit Therapeutics SMMT Stock Holding History

Snowden Capital Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,192
Closed -$314K – 1323
2025
Q3 		$314K Buy
15,192
+277
+2% +$6.72K 0.01% 1003
2025
Q2 		$317K Buy
+14,915
New +$340K 0.01% 970
2023
Q3 		– Sell
-12,500
Closed -$31.4K – 1181
2023
Q2 		$31.4K Buy
+12,500
New +$22.8K ﹤0.01% 1162

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Snowden Capital Advisors's SMMT Position: Q4 2025 in Review

Snowden Capital Advisors sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 15,192 shares — an estimated $314K sold.

Snowden Capital Advisors first reported a position in SMMT in Q2 2023 and held it in 3 quarters. The position peaked at $317K in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • Snowden Capital Advisors reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Snowden Capital Advisors sold 15,192 Summit Therapeutics shares in Q4 2025, an estimated $314K.
  • Snowden Capital Advisors first reported a position in Summit Therapeutics in Q2 2023 and held it in 3 quarters.
  • Snowden Capital Advisors's Summit Therapeutics position peaked at $317K in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Snowden Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.